AbbVie sees 37% drop in Humira sales this year as biosimilars hit U.S. market

📆 10/02/2023 01:40 ص
📰 Reuters

⏱ Reading Time:
15 sec. here
2 min. at publisher
📊 Quality Score:
News: 9%
Publisher: 97%

الإمارات العربية المتحدة أخبار أخبار

الإمارات العربية المتحدة أحدث الأخبار,الإمارات العربية المتحدة عناوين

AbbVie Inc said on Thursday it expects sales of its flagship rheumatoid arthritis drug Humira to decline 37% this year due to competition from cheaper biosimilars in the United States, but sees that stabilizing by the end of 2024.

Amjevita, the first biosimilar competition for Humira in the United States. At least seven others are expected to debut this summer.

Overall, Humira sales rose 4.6% to $5.58 billion, in line with estimates, lifted by growth in the U.S. market. Skyrizi sales of $1.58 billion beat analysts' estimates of $1.52 billion, while Rinvoq missed with $770 million in sales compared with expectations of $816.14 million.

اكتب تعليق

لقد قمنا بتلخيص هذا الخبر حتى تتمكن من قراءته بسرعة. إذا كنت مهتمًا بالأخبار، يمكنك قراءة النص الكامل هنا. اقرأ أكثر:

الإمارات العربية المتحدة أحدث الأخبار, الإمارات العربية المتحدة عناوين